- Stocks
- Pharma & Healthcare
- Mercury Labs
Mercury Labs share price
NSE: MERCURYLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Mercury Labs at a glance
With a market capitalisation of ₹102 Cr, it ranks 2667th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 5.9% in FY25. Promoters held 73.66% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹102 CrRank 2667 on NSE
- Price to book
- 1.83×FY25
- ROE
- 5.9%FY25
- ROCE
- 8.8%FY25
- Debt to equity
- 0.08FY25
- Net profit margin
- 4.2%FY25
- Book value / share
- ₹446.41FY25
- Dividend payout
- 13.4%FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Mercury Labs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹57 Cr | ₹69 Cr | ₹58 Cr | ₹75 Cr | ₹76 Cr | ₹75 Cr |
| Operating profit | ₹4 Cr | ₹8 Cr | ₹5 Cr | ₹7 Cr | ₹7 Cr | ₹5 Cr |
| Net profit | ₹3 Cr | ₹5 Cr | ₹4 Cr | ₹6 Cr | ₹6 Cr | ₹3 Cr |
| EPS (₹) | ₹26.90 | ₹44.48 | ₹30.72 | ₹46.49 | ₹47.12 | ₹26.21 |
| Cash from operations | ₹5 Cr | ₹8 Cr | ₹5 Cr | ₹2 Cr | ₹8 Cr | ₹4 Cr |
| Total debt | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr |
| Shareholders' equity | ₹32 Cr | ₹37 Cr | ₹40 Cr | ₹46 Cr | ₹51 Cr | ₹54 Cr |
Mercury Labs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% |
| Non-institutions | 26.34% | 26.34% | 26.34% | 26.34% | 26.34% | 26.34% |
Mercury Labs vs peers
The listed Pharma & Healthcare companies nearest to Mercury Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MERCURYLABMercury Labs | — | — | — | ₹102 Cr | — | — |
| VAISHALIVaishali Pharma | ₹7.49 | +2.04% | −30.3% | ₹101 Cr | 124.8 | — |
| CONCORDConcord Drugs | — | — | — | ₹101 Cr | — | — |
| DENISCHEMDenis Chem Lab | — | — | — | ₹101 Cr | — | — |
| FORTISMLRFortis Malar | — | — | — | ₹97 Cr | — | — |
| RAAJMEDIRaaj Medisafe | — | — | — | ₹97 Cr | — | — |
| KHFMKHFM HOSPITALIT | ₹40.90 | +4.87% | −50.1% | ₹95 Cr | — | — |
Ask anything about Mercury Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against MERCURYLAB's own history. Try: “Why has MERCURYLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on MERCURYLAB over five years” · “Compare MERCURYLAB with VAISHALI on margins and valuation”
Frequently asked questions about Mercury Labs
What is the market cap of Mercury Labs?
Mercury Labs' market capitalisation is ₹102 Cr (₹102 Cr) at the 22 Oct 2026 close, ranking 2667th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Mercury Labs?
Return on equity was 5.9% in FY25 and return on capital employed was 8.8% in FY25 (standalone figures).
Is Mercury Labs a debt-free company?
No. Mercury Labs' debt-to-equity ratio was 0.08 in FY25, with total debt of ₹3 Cr.
What is the shareholding pattern of Mercury Labs?
As of 30 Jun 2026: promoters 73.66%, non-institutions 26.34%.
Who are Mercury Labs' competitors?
The listed Pharma & Healthcare companies closest to Mercury Labs by market cap are Vaishali Pharma, Concord Drugs, Denis Chem Lab, Fortis Malar, Raaj Medisafe and KHFM HOSPITALIT.
Is Mercury Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Mercury Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MERCURYLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text